title: Antihypertensive effect of diltiazem in a slow-release formulation for mild to moderate essential hypertension.
abstract: The antihypertensive efficacy and frequency of adverse reactions following administration of diltiazem in a new slow-release formulation were compared with placebo in 34 patients with mild to moderate essential hypertension in a randomized, double-blind, crossover study. After 6 weeks of treatment with diltiazem (240 or 360 mg/day), average supine blood pressure (BP) decreased from 165 +/- 21/101 +/- 5 mm Hg at baseline to 152 +/- 16/93 +/- 4 mm Hg compared with 160 +/- 19/100 +/- 7 mm Hg with placebo (p less than 0.01/p less than 0.001). Standing BP decreased from 162 +/- 20/107 +/- 6 mm Hg at baseline to 150 +/- 14/101 +/- 5 mm Hg compared to 159 +/- 18/107 +/- 8 mm Hg with placebo (p less than 0.01/p less than 0.001). The supine heart rate after diltiazem was 65 +/- 7 beats/min and after placebo 69 +/- 9 beats/min (p less than 0.01). There were no hematologic side effects. Only minor differences between diltiazem and placebo were observed in some of the biochemical laboratory values. Four patients were withdrawn due to side effects during treatment with diltiazem and 2 with placebo. Diltiazem in a slow-release formulation given twice a day lowered blood pressure significantly as monotherapy in patients with mild to moderate hypertension and was well tolerated.
authors.affiliation: Department of Clinical Sciences, University of Tampere, Finland.
authors.forename: M T
authors.initials: MT
authors.lastname: Nikkilä
authors.forename: J A
authors.initials: JA
authors.lastname: Inkovaara
authors.forename: J T
authors.initials: JT
authors.lastname: Heikkinen
authors.forename: S O
authors.initials: SO
authors.lastname: Olsson
mesh_terms: D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations; D004110:Diltiazem / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D013484:Supination
chemical_list: D003692:Delayed-Action Preparations; D004110:Diltiazem